Initial use of fixed-dose angiotensin receptor blocker/hydrochlorothiazide therapy may improve hypertension management, reduce risk of cardiovascular disease, and decrease long-term healthcare expenditures.
C. Venkata S. Ram, MD
Advertisement
Articles by C. Venkata S. Ram, MD
Advertisement
Latest Updated Articles
- Reduced Cardiovascular Risk and Healthcare Expenditures With Angiotensin Receptor Blocker/ Hydrochlorothiazide
Published: April 27th 2010 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
COVID-19 mRNA Vaccines May Boost Immunotherapy Response in Cancer
2
FDA, HHS Move to Accelerate Biosimilar Approvals
3
KEYNOTE Trial Data Presented at ESMO 2025 Congress Reiterate Pembrolizumab’s Benefits in NSCLC
4
Accelerated Approval of Cancer Drugs: Benefit or Burden?
5
